Search results
Tresiba vs. Lantus: Similarities and Differences
Verywell Health via Yahoo News· 4 months agoTresiba (insulin degludec) and Lantus (insulin glargine) are Food and Drug Administration (FDA)-approved synthetic insulins for glycemic control (blood...
There’s a problem that caused one batch of insulin injection pens to be recalled
Miami Herald via AOL· 2 years agoMylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL...
Wegovy and Ozempic Maker Novo Nordisk Shares Data From Phase 3 Diabetes Study Of Semaglutide/Insulin...
Benzinga via Yahoo Finance· 4 months agoNovo Nordisk A/S (NYSE: NVO) announced topline results from the COMBINE 3 phase 3a trial of...
Eli Lilly’s efsitora alfa shows promise in Phase III T2D trials
Clinical Trials Arena via Yahoo Finance· 1 week agoEli Lilly has reported positive outcomes from the Phase III QWINT-2 and QWINT-4 clinical trials of...
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
Zacks via Yahoo Finance· 4 months agoNovo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the...
Novo Nordisk says weekly IcoSema superior to daily insulin glargine, aspart
Reuters via Yahoo News· 4 months agoCOPENHAGEN (Reuters) - Denmark's Novo Nordisk said on Monday its COMBINE 3 phase 3a drug trial had...
Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data
Zacks via Yahoo Finance· 11 months agoNovo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on...
Lilly's weekly insulin as effective as daily doses in studies
Reuters via Yahoo News· 1 week agoLilly and Novo Nordisk are both developing weekly injections for long-acting insulins that could...
Lilly’s once-weekly insulin matches daily shots in late-stage tests
BioPharma Dive via Yahoo Finance· 1 week agoThe results, which showed Lilly’s drug was as effective at controlling blood sugar as standard...
Novo Nordisk (NVO) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 months agoImage source: The Motley Fool. Novo Nordisk (NYSE: NVO) Q4 2023 Earnings Call Jan 31, 2024, 7:00 a.m. ET Contents: Prepared Remarks Questions and Answers...